Reversion of HIV Resistance Mutations During Treatment Interruption
Author Information
Author(s): Agnes C. Paquet, John Baxter, Jodi Weidler, Yolanda Lie, Jody Lawrence, Rose Kim, Michael Bates, Eoin Coakley, Colombe Chappey
Primary Institution: Monogram Biosciences, Inc.
Hypothesis
How does structured treatment interruption affect the reversion of resistance mutations in HIV?
Conclusion
The study found significant variability in the reversion rates of HIV resistance mutations during structured treatment interruption, with some mutations reverting faster than others.
Supporting Evidence
- Median replication capacity increased from 47.5% at baseline to 86.0% at 2 months and to 97.5% at 4 months.
- T215F had the fastest rate of reversion at 41% between baseline and 2 months.
- Patients with higher baseline CD4 counts showed significantly higher reversion rates.
Takeaway
When HIV treatment is paused, some of the virus's resistance to drugs can go away, but how quickly this happens can be different for each person.
Methodology
The study analyzed data from 90 patients who underwent structured treatment interruption for 4 months, measuring changes in viral replication capacity and resistance mutations at baseline, 2 months, and 4 months.
Potential Biases
Some patients were excluded due to missing data, which may introduce bias.
Limitations
The study was limited to RT resistance mutations and did not include protease inhibitors.
Participant Demographics
Patients included had multi-drug resistant HIV and varied baseline CD4 counts.
Statistical Information
P-Value
<2.2e-16
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website